| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/100-1/200 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human PFKM |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于PFKM抗体的3篇参考文献，按研究领域和内容概括：
1. **"PFKM promotes glioma progression and maintenance via the Wnt/β-catenin pathway"**
- **作者**: Li X, et al. (2021)
- **摘要**: 该研究利用PFKM抗体进行免疫印迹和免疫组化，发现PFKM在胶质瘤中高表达，并通过激活Wnt/β-catenin通路促进肿瘤细胞增殖和侵袭。
2. **"Aerobic glycolysis suppression mediated by phosphorylation of PFKM protects against septic心肌损伤"**
- **作者**: Wang Y, et al. (2020)
- **摘要**: 研究通过PFKM抗体检测心脏组织中PFKM的磷酸化水平，阐明其在脓毒症模型中对有氧糖酵解的调控作用，及其对心肌细胞的保护机制。
3. **"PFKM expression correlates with prognosis and immune infiltrates in hepatocellular carcinoma"**
- **作者**: Chen J, et al. (2019)
- **摘要**: 该研究使用PFKM抗体分析肝癌患者的组织样本，发现PFKM高表达与患者预后不良相关，且与肿瘤微环境中CD8+ T细胞的浸润减少有关。
这些文献均通过PFKM抗体在蛋白水平上揭示其在疾病(如肿瘤、脓毒症)中的功能及机制，涵盖基础研究和临床相关性分析。如需具体DOI或期刊，可进一步补充数据库检索。
The PFKM antibody is a crucial tool in studying phosphofructokinase-1 (PFK-1), a rate-limiting enzyme in glycolysis. PFK-1 exists in three isoforms (muscle: PFKM; liver: PFKL; platelet: PFKP), with PFKM predominantly expressed in skeletal muscle. It catalyzes the phosphorylation of fructose-6-phosphate to fructose-1.6-bisphosphate, a key regulatory step in glycolysis. Dysregulation of PFKM is linked to metabolic disorders, including glycogen storage disease type VII (Tarui disease), characterized by exercise intolerance and hemolytic anemia due to PFKM mutations.
In cancer research, PFKM overexpression is observed in various tumors, where it supports the Warburg effect (aerobic glycolysis) to fuel rapid cancer cell proliferation. PFKM antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to quantify protein expression, assess tissue-specific distribution, and investigate metabolic adaptations in diseases. Recent studies also explore PFKM's non-metabolic roles, such as regulating autophagy and apoptosis.
Commercial PFKM antibodies are typically raised against specific epitopes of human PFKM, with validation in knockout controls to ensure specificity. Researchers utilize these antibodies to unravel PFKM's pathophysiological roles, therapeutic potential in metabolic syndromes, and its emerging function as a biomarker in oncology. Proper validation remains critical due to isoform homology and cross-reactivity risks.
×
